Coregistration of Magnetic Resonance and [18F] Fludeoxyglucose–Positron Emission Tomography Imaging for Stereotactic Radiation Therapy Planning: Case Report in a Previously Irradiated Brain Metastasis With Recurrent Tumor and Radiation Necrosis

Scranton, Robert A.; Sadrameli, Saeed S.; Butler, E. Brian; Farach, Andrew M.; Wang, Hui-Chuan; Teh, Bin S.; Tremont‐Lukats, Ivo W.; Fung, Steve H.; Zanotti‐Fregonara, Paolo; Rostomily, Robert

doi:10.1016/j.prro.2019.11.008

Cited by 4 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Integration of PET/CT in radiotherapy planning is common in many cancer types [10], and PET/MRI is now increasingly being used in RTP [36][37][38][39][40][41]. In prostate cancer, several studies have also evaluated the use of PSMA PET/MRI in the radiotherapy of primary and recurrent prostate cancer [16,42,43].…”

Section: Discussionmentioning

confidence: 99%

Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer

Liu

Zhu

et al. 2023

Cancer Imaging

View full text Add to dashboard Cite

Purpose A comparative retrospective study to assess the impact of PSMA Ligand PET/MRI ([68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 PET/MRI) as a new method of target delineation compared to conventional imaging on whole-pelvis radiotherapy for high-risk prostate cancer (PCa). Patients and methods Forty-nine patients with primary high-risk PCa completed the whole-pelvis radiotherapy plan based on PSMA PET/MRI and MRI. The primary endpoint compared the size and overlap of clinical target volume (CTV) and nodal gross tumour volume (GTVn) based on PSMA PET/MRI and MRI. The diagnostic performance of two methods for pelvic lymph node metastasis (PLNM) was evaluated. Results In the radiotherapy planning for high-risk PCa patients, there was a significant correlation between MRI-CTV and PET/MRI-CTV (P = 0.005), as well as between MRI-GTVn and PET/MRI-GTVn (P < 0.001). There are non-significant differences in the CTV and GTVn based on MRI and PET/MRI images (P = 0.660, P = 0.650, respectively). The conformity index (CI), lesion coverage factor (LCF) and Dice similarity coefficient (DSC) of CTVs were 0.999, 0.953 and 0.954. The CI, LCF and DSC of GTVns were 0.927, 0.284, and 0.32. Based on pathological lymph node analysis of 463 lymph nodes from 37 patients, the sensitivity, specificity of PET/MRI in the diagnosis of PLNM were 77.78% and 99.76%, respectively, which were higher than those of MRI (P = 0.011). Eight high-risk PCa patients who finished PSMA PET/MRI changed their N or M stage. Conclusion The CTV delineated based on PET/MRI and MRI differ little. The GTVn delineated based on PET/MRI encompasses metastatic pelvic lymph nodes more accurately than MRI and avoids covering pelvic lymph nodes without metastasis. We emphasize the utility of PET/MRI fusion images in GTVn delineation in whole pelvic radiotherapy for PCa. The use of PSMA PET/MRI aids in the realization of more individual and precise radiotherapy for PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer

Liu

Zhu

et al. 2023

Cancer Imaging

View full text Add to dashboard Cite

show abstract

“…Comparable results were observed in a study showing that combination of apparent diffusion coefficient (ADC) and FET was more accurate to detect glioma infiltration than standard MRI in enhancing gliomas ( 38 ); such an approach could allow risk-adapted radiotherapy planning ( 39 ). Finally, for brain metastasis, FDG PET associated with MRI could be interesting for lesion targeting of stereotactic radiation therapy in case of a previously irradiated recurrent tumor ( 40 ); place of FDOPA in this indication has yet to be evaluated.…”

Section: Clinical Applicationsmentioning

confidence: 99%

Trimodality PET/CT/MRI and Radiotherapy: A Mini-Review

Decazes

Hinault

Veresezan³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Computed tomography (CT) has revolutionized external radiotherapy by making it possible to visualize and segment the tumors and the organs at risk in a three-dimensional way. However, if CT is a now a standard, it presents some limitations, notably concerning tumor characterization and delineation. Its association with functional and anatomical images, that are positron emission tomography (PET) and magnetic resonance imaging (MRI), surpasses its limits. This association can be in the form of a trimodality PET/CT/MRI. The objective of this mini-review is to describe the process of performing this PET/CT/MRI trimodality for radiotherapy and its potential clinical applications. Trimodality can be performed in two ways, either a PET/MRI fused to a planning CT (possibly with a pseudo-CT generated from the MRI for the planning), or a PET/CT fused to an MRI and then registered to a planning CT (possibly the CT of PET/CT if calibrated for radiotherapy). These examinations should be performed in the treatment position, and in the second case, a patient transfer system can be used between the PET/CT and MRI to limit movement. If trimodality requires adapted equipment, notably compatible MRI equipment with high-performance dedicated coils, it allows the advantages of the three techniques to be combined with a synergistic effect while limiting their disadvantages when carried out separately. Trimodality is already possible in clinical routine and can have a high clinical impact and good inter-observer agreement, notably for head and neck cancers, brain tumor, prostate cancer, cervical cancer.

show abstract

“…[77][78][79] Finally, new approaches that use metabolic and functional imaging for treatment planning may provide more precise and safe targeting for recurrent treated tumors and those near functional structures such as the corticospinal tracts. 80…”

Section: Clinical Radiotherapymentioning

confidence: 99%

Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience

et al. 2020

Self Cite

View full text Add to dashboard Cite

Systemic therapies for primary breast cancer have made great progress over the past two decades. However, oncologists confront an insidious and particularly difficult problem: in those patients with metastatic breast cancer, up to 50% of human epidermal growth factor 2 (HER2)-positive and 25–40% of triple-negative subtypes, brain metastases (BM) kill most of them. Fortunately, standard- of-care treatments for BM have improved rapidly, with a decline in whole brain radiation therapy and use of fractionated stereotactic radiosurgery as well as targeted therapies and immunotherapies. Meanwhile, advances in fundamental understanding of the basic biological processes of breast cancer BM (BCBM) have led to many novel experimental therapeutic strategies. In this review, we describe the most recent clinical treatment options and emerging experimental therapeutic strategies that have the potential to combat BCBM.

show abstract

Coregistration of Magnetic Resonance and [18F] Fludeoxyglucose–Positron Emission Tomography Imaging for Stereotactic Radiation Therapy Planning: Case Report in a Previously Irradiated Brain Metastasis With Recurrent Tumor and Radiation Necrosis

Cited by 4 publications

References 23 publications

Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer

Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer

Trimodality PET/CT/MRI and Radiotherapy: A Mini-Review

Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience

Contact Info

Product

Resources

About